Skip to main content
Top
Published in: Abdominal Radiology 4/2005

01-08-2005

Radiofrequency ablation of neuroendocrine liver metastases—the Middlesex experience

Authors: A. Gillams, A. Cassoni, G. Conway, W. Lees

Published in: Abdominal Radiology | Issue 4/2005

Login to get access

Abstract

Background

Current treatment options for neuroendocrine liver metastases are not widely applicable or not that effective. Image-guided thermal ablation offers the possibility of a minimally invasive, albeit palliative, treatment that decreases tumor volume, preserves most of the normal liver, and can be repeated several times. We report our experience with image-guided thermal ablation in 25 patients with unresectable liver metastases.

Methods

Since 1990 we have treated 189 tumors at 66 treatment sessions in 25 patients (12 female, 13 male; median age, 56 years; age range, 26–78 years). Thirty treatments were performed with a solid-state laser, and 36 treatments were performed with radiofrequency ablation. All but one treatment was performed percutaneously under image guidance. Sixteen patients had metastases from carcinoid primaries, three from gastrinoma, two from insulinoma, and four from miscellaneous causes. Fourteen of 25 had symptoms from hormone secretion.

Results

Imaging follow-up was available in 19 patients at a median of 21 months (range, 4–75 months). There was a complete response in six patients, a partial response in seven, and stable disease in one; hence, tumor load was controlled in 14 of 19 patients (74%). Relief of hormone-related symptoms was achieved in nine of 14 patients (69%). The median survival period from the diagnosis of liver metastases was 53 months. One patient with end-stage cardiac disease died after a carcinoid crisis. There were eight (12%) complications: five local and three distant, four major and four minor.

Conclusions

As a minimally invasive, readily repeatable procedure that can be used to ablate small tumors, preferably before patients become severely symptomatic, radiofrequency ablation can provide effective control of liver tumor volume in most patients over many years.
Literature
1.
go back to reference Oberg, K 1993The use of chemotherapy in the management of neuroendocrine tumorsEndocrinol Metab Clin North Am22941PubMed Oberg, K 1993The use of chemotherapy in the management of neuroendocrine tumorsEndocrinol Metab Clin North Am22941PubMed
2.
go back to reference Chamberlain, R, Canes, D, Brown, K, et al. 2000Hepatic neuroendocrine metastases: does intervention alter outcomes?J Am Coll Surg190432445CrossRefPubMed Chamberlain, R, Canes, D, Brown, K,  et al. 2000Hepatic neuroendocrine metastases: does intervention alter outcomes?J Am Coll Surg190432445CrossRefPubMed
3.
go back to reference Eriksson, B, Skogseid, B, Lundquist, G, et al. 1990Medical treatment and long term survival in a prospective study of 84 patients with endocrine pancreatic tumoursCancer6518831890PubMed Eriksson, B, Skogseid, B, Lundquist, G,  et al. 1990Medical treatment and long term survival in a prospective study of 84 patients with endocrine pancreatic tumoursCancer6518831890PubMed
4.
go back to reference Chung, M, Pisegna, J, Spirt, M, et al. 2001Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liverSurgery130954962CrossRefPubMed Chung, M, Pisegna, J, Spirt, M,  et al. 2001Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liverSurgery130954962CrossRefPubMed
5.
go back to reference Chen, H, Hardacre, J, Uzar, A, et al. 1998Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg1878893CrossRefPubMed Chen, H, Hardacre, J, Uzar, A,  et al. 1998Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg1878893CrossRefPubMed
6.
go back to reference Ruszniewski, P, Malka, D 2000Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumorsDigestion627983CrossRefPubMed Ruszniewski, P, Malka, D 2000Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumorsDigestion627983CrossRefPubMed
7.
go back to reference Roche, A, Girish, B, Baere, T, et al. 2003Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumoursEur Radiol13136140PubMed Roche, A, Girish, B, Baere, T,  et al. 2003Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumoursEur Radiol13136140PubMed
8.
go back to reference Rougier, P, Mitry, E 2000Chemotherapy in the treatment of neuroendocrine malignant tumorsDigestion627378CrossRef Rougier, P, Mitry, E 2000Chemotherapy in the treatment of neuroendocrine malignant tumorsDigestion627378CrossRef
10.
go back to reference Arnold, R, Simon, B, Wied, M 2000Treatment of neuroendocrine GEP tumours with somatostatin analoguesDigestion628491CrossRefPubMed Arnold, R, Simon, B, Wied, M 2000Treatment of neuroendocrine GEP tumours with somatostatin analoguesDigestion628491CrossRefPubMed
11.
go back to reference Sarmiento, J, Heywood, G, Rubin, J, et al. 2003Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survivalJ Am Coll Surg1972937CrossRefPubMed Sarmiento, J, Heywood, G, Rubin, J,  et al. 2003Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survivalJ Am Coll Surg1972937CrossRefPubMed
12.
go back to reference Bomanji, J, Wong, W, Gaze, M, et al. 2003Treatment of neuroendocrine tumours in adults with I131-MIBG (review)Clin Oncol15193198CrossRef Bomanji, J, Wong, W, Gaze, M,  et al. 2003Treatment of neuroendocrine tumours in adults with I131-MIBG (review)Clin Oncol15193198CrossRef
13.
go back to reference Eriksson, B, Renstrup, J, Imam, H, Oberg, K 1997High-dose treatment with lanreotide of patients with advanced gastrointestinal tumors: clinical and biochemical effectsAnn Oncol810411044CrossRefPubMed Eriksson, B, Renstrup, J, Imam, H, Oberg, K 1997High-dose treatment with lanreotide of patients with advanced gastrointestinal tumors: clinical and biochemical effectsAnn Oncol810411044CrossRefPubMed
14.
go back to reference Gillams, A, Lees, W 2002Radiofrequency ablation in patients with biliary obstruction, biliary stents or bilio-enteric anastomosesRadiology225488 Gillams, A, Lees, W 2002Radiofrequency ablation in patients with biliary obstruction, biliary stents or bilio-enteric anastomosesRadiology225488
15.
go back to reference Siperstein, A, Roger, S, Jamsem, P, Gitomirsky, A 1997Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastasesSurgery12211471155CrossRefPubMed Siperstein, A, Roger, S, Jamsem, P, Gitomirsky, A 1997Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastasesSurgery12211471155CrossRefPubMed
16.
go back to reference Berber, E, Flesher, N, Siperstein, A 2002Laparoscopic radiofrequency ablation of neuroendocrine liver metastasesWorld J Surg26985990CrossRefPubMed Berber, E, Flesher, N, Siperstein, A 2002Laparoscopic radiofrequency ablation of neuroendocrine liver metastasesWorld J Surg26985990CrossRefPubMed
17.
go back to reference Hellman, P, Ladjevardi, S, Skogseid, B, et al. 2002Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumorsWorld J Surg2610521056CrossRefPubMed Hellman, P, Ladjevardi, S, Skogseid, B,  et al. 2002Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumorsWorld J Surg2610521056CrossRefPubMed
18.
go back to reference Kaltsas, G, Mukherjee, J, Grossman, A 2001The value of radiolabelled mibg and octreotide in the diagnosis and management of neuroendocrine tumoursAnn Oncol12S47S50CrossRefPubMed Kaltsas, G, Mukherjee, J, Grossman, A 2001The value of radiolabelled mibg and octreotide in the diagnosis and management of neuroendocrine tumoursAnn Oncol12S47S50CrossRefPubMed
19.
go back to reference Olausson, M, Friman, S, Cahlin, C, et al. 2002Indications and results of liver transplantation in patients with neuroendocrine tumoursWorld J Surg269981004CrossRefPubMed Olausson, M, Friman, S, Cahlin, C,  et al. 2002Indications and results of liver transplantation in patients with neuroendocrine tumoursWorld J Surg269981004CrossRefPubMed
20.
go back to reference Lehnert, T 1998Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patientsTransplantation6613071312CrossRefPubMed Lehnert, T 1998Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patientsTransplantation6613071312CrossRefPubMed
21.
go back to reference Siperstein, A, Berber, E 2001Cryoablation, percutaneous ethanol injection and radiofrequency ablation for treatment of neuroendocrine liver metastasesWorld J Surg25696696CrossRef Siperstein, A, Berber, E 2001Cryoablation, percutaneous ethanol injection and radiofrequency ablation for treatment of neuroendocrine liver metastasesWorld J Surg25696696CrossRef
Metadata
Title
Radiofrequency ablation of neuroendocrine liver metastases—the Middlesex experience
Authors
A. Gillams
A. Cassoni
G. Conway
W. Lees
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 4/2005
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-004-0258-4

Other articles of this Issue 4/2005

Abdominal Radiology 4/2005 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.